← All trials
NCT05529927
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Apr 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Sep 7, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 204
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Parnassia Addiction Research CentreLead sponsor
- University of AmsterdamCollaborator
- Columbia UniversityCollaborator
- Leiden UniversityCollaborator
- Parnassia Addiction Research CentreOverall official - principal investigator
- Parnassia Addiction Research CentreReponsible party - principal investigator
- Radboud UniversityCollaborator
- Netherlands Cancer InstituteCollaborator
- Parnassia Addiction Research CentreSponsor investigator
- Parnassia Addiction Research CentreOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.